Biomarkers Market Size (2024 - 2029)

The biomarkers market is projected to experience significant growth over the forecast period, driven by the increasing prevalence of cancer and cardiac conditions, alongside advancements in biomarker technology. The rising demand for accurate disease diagnosis and treatment, particularly for life-threatening diseases like cancer and Alzheimer's, is contributing to the expansion of the market. The introduction of innovative biomarker tests by industry players further supports market growth. However, challenges such as regulatory and reimbursement issues, as well as the high costs associated with biomarkers, may impede the market's expansion.

Market Size of Biomarkers Industry

Biomarkers Market Summary
Study Period 2019 - 2029
Market Size (2024) USD 51.5 Billion
Market Size (2029) USD 87.60 Billion
CAGR (2024 - 2029) 11.21 %
Fastest Growing Market Asia Pacific
Largest Market North America
Market Concentration Medium

Major Players

Biomarkers Market Major Players

*Disclaimer: Major Players sorted in no particular order

Biomarkers Market Analysis

The Biomarkers Market size is estimated at USD 51.5 billion in 2024, and is expected to reach USD 87.60 billion by 2029, growing at a CAGR of 11.21% during the forecast period (2024-2029).

Factors such as the high prevalence of cancer and cardiac problems and biomarker advancements can be attributed to the growth of the biomarkers market. The spike in cancer cases globally has increased the use of advanced technology such as biomarkers. For instance, according to an article published by the Chinese Medical Journal in March 2022, approximately 4.8 million new cancer cases were registered in China in 2022, out of which the most common was lung cancer. Such an increase in the burden of cancer will likely push companies to develop newer targets for cancer diagnosis, ultimately boosting the demand for biomarkers over the coming years.

According to an article published by PubMed Central in April 2022, new electroencephalogram (EEG) based non-invasive techniques with bodily fluid biomarkers are being developed, which may offer a more accurate prediction of Alzheimer’s disease status in the patient. The article also stated that several minimally invasive techniques are being developed, and several biomarkers are being found to predict Alzheimer’s disease from blood, saliva, and urine. Thus, with the increasing prevalence of life-threatening diseases and the rising usage of biomarkers in diagnosing and treating those diseases, the demand for biomarkers in accurately diagnosing the condition is anticipated to grow, boosting the market's growth.

The launch of biomarker tests by market players is also augmenting the market's growth. For instance, in July 2022, Labcorp launched one of the first widely accessible tests that provide direct evidence of neurodegeneration and neuronal injury. The Neurofilament Light Chain (NfL) is a blood biomarker test that allows doctors to identify and verify signs of neurodegenerative disease, providing a more effective and efficient path to diagnosis and treatment for patients. Elevated NfL levels signal neuronal injury, whether from diseases like multiple sclerosis, Alzheimer’s, and Parkinson’s, or brain injury, such as concussion.

Thus, owing to the above-mentioned factors, such as the rising prevalence of life-threatening diseases, the rising usage of biomarkers in disease diagnosis, and increasing product launches, the market is expected to grow over the forecast period. However, issues related to regulatory and reimbursement systems and the high cost of biomarkers may hinder the market's growth.

Biomarkers Industry Segmentation

As per the scope of the report, a biomarker refers to a biomolecule or gene used to precisely evaluate the body's pharmacologic, pathogenic, and biological procedures. They serve as an early warning system in the body. It can also be stated as a traceable subsite introduced into the body to check or examine the organ's function. It can be measured and evaluated by using blood, urine, or soft tissues. 

The biomarkers market is segmented by disease, type, mechanism, and geography. By disease, the market is segmented into cancer, cardiovascular disorders, neurological disorders, immunological disorders, renal disorders, and other diseases. By type, the market is segmented into efficacy biomarkers, safety biomarkers, and validation biomarkers. By mechanism, the market is segmented into genetic, epigenetic, proteomic, lipidomic, and other mechanisms. By geography, the market is segmented into North America, Europe, Asia-Pacific, the Middle East and Africa, and South America. The report also covers the estimated market sizes and trends for 17 countries across major global regions. The report offers the value (USD) for all the above-mentioned segments.

By Disease
Cancer
Cardiovascular Disorders
Neurological Disorders
Immunological Disorders
Renal Disorders
Other Diseases
By Type
Efficacy Biomarkers
Prognostic Biomarkers
Pharmacodynamic Biomarkers
Surrogate End Point Markers
Predictive Biomarkers
Safety Biomarkers
Validation Biomarkers
By Mechanism
Genetic Biomarkers
Epigenetic Biomarkers
Proteomic Biomarkers
Lipidomic Biomarkers
Other Mechanisms
Geography
North America
United States
Canada
Mexico
Europe
Germany
United Kingdom
France
Italy
Spain
Rest of Europe
Asia-Pacific
China
Japan
India
Australia
South Korea
Rest of Asia-Pacific
Middle East and Africa
GCC
South Africa
Rest of Middle East and Africa
South America
Brazil
Argentina
Rest of South America
Need A Different Region Or Segment?
Customize Now

Biomarkers Market Size Summary

The biomarkers market is poised for significant growth, driven by the increasing prevalence of cancer and cardiac conditions, alongside advancements in biomarker technology. The rising incidence of cancer globally has necessitated the adoption of advanced diagnostic tools, including biomarkers, to enhance cancer detection and treatment. Similarly, the development of non-invasive techniques for predicting Alzheimer's disease using bodily fluid biomarkers underscores the expanding role of biomarkers in diagnosing and managing life-threatening diseases. The introduction of innovative biomarker tests by key market players further propels market expansion, despite challenges related to regulatory and reimbursement frameworks and the high costs associated with biomarker applications.

Epigenetic biomarkers are gaining traction due to their ability to detect and quantify epigenetic changes through minimally invasive procedures, offering promising applications in disease identification, staging, and clinical management. The growing prevalence of lifestyle-related diseases and cancer, coupled with strategic initiatives by market players, is expected to drive the segment's growth. North America is anticipated to hold a substantial share of the biomarkers market, supported by the increasing approval of molecular biomarker-based drug labels and a high burden of neurological conditions. The market's competitive landscape is characterized by significant investments in research and development, with major pharmaceutical companies and governments focusing on technological advancements to foster market growth.

Explore More

Biomarkers Market Size - Table of Contents

  1. 1. MARKET DYNAMICS

    1. 1.1 Market Overview

    2. 1.2 Market Drivers

      1. 1.2.1 Rising Prevalence of Life Threatening Diseases

      2. 1.2.2 Increasing Demand for Early Diagnosis of Diseases

      3. 1.2.3 Research Advancements in Finding New Biomarkers

    3. 1.3 Market Restraints

      1. 1.3.1 Issues Related to Regulatory and Reimbursement Systems

      2. 1.3.2 High Cost of Biomarkers

    4. 1.4 Porter's Five Forces Analysis

      1. 1.4.1 Bargaining Power of Suppliers

      2. 1.4.2 Bargaining Power of Buyers/Consumers

      3. 1.4.3 Threat of New Entrants

      4. 1.4.4 Threat of Substitute Products

      5. 1.4.5 Intensity of Competitive Rivalry

  2. 2. MARKET SEGMENTATION (Market Size by Value – USD)

    1. 2.1 By Disease

      1. 2.1.1 Cancer

      2. 2.1.2 Cardiovascular Disorders

      3. 2.1.3 Neurological Disorders

      4. 2.1.4 Immunological Disorders

      5. 2.1.5 Renal Disorders

      6. 2.1.6 Other Diseases

    2. 2.2 By Type

      1. 2.2.1 Efficacy Biomarkers

        1. 2.2.1.1 Prognostic Biomarkers

        2. 2.2.1.2 Pharmacodynamic Biomarkers

        3. 2.2.1.3 Surrogate End Point Markers

        4. 2.2.1.4 Predictive Biomarkers

      2. 2.2.2 Safety Biomarkers

      3. 2.2.3 Validation Biomarkers

    3. 2.3 By Mechanism

      1. 2.3.1 Genetic Biomarkers

      2. 2.3.2 Epigenetic Biomarkers

      3. 2.3.3 Proteomic Biomarkers

      4. 2.3.4 Lipidomic Biomarkers

      5. 2.3.5 Other Mechanisms

    4. 2.4 Geography

      1. 2.4.1 North America

        1. 2.4.1.1 United States

        2. 2.4.1.2 Canada

        3. 2.4.1.3 Mexico

      2. 2.4.2 Europe

        1. 2.4.2.1 Germany

        2. 2.4.2.2 United Kingdom

        3. 2.4.2.3 France

        4. 2.4.2.4 Italy

        5. 2.4.2.5 Spain

        6. 2.4.2.6 Rest of Europe

      3. 2.4.3 Asia-Pacific

        1. 2.4.3.1 China

        2. 2.4.3.2 Japan

        3. 2.4.3.3 India

        4. 2.4.3.4 Australia

        5. 2.4.3.5 South Korea

        6. 2.4.3.6 Rest of Asia-Pacific

      4. 2.4.4 Middle East and Africa

        1. 2.4.4.1 GCC

        2. 2.4.4.2 South Africa

        3. 2.4.4.3 Rest of Middle East and Africa

      5. 2.4.5 South America

        1. 2.4.5.1 Brazil

        2. 2.4.5.2 Argentina

        3. 2.4.5.3 Rest of South America

Biomarkers Market Size FAQs

The Biomarkers Market size is expected to reach USD 51.5 billion in 2024 and grow at a CAGR of 11.21% to reach USD 87.60 billion by 2029.

In 2024, the Biomarkers Market size is expected to reach USD 51.5 billion.

Biomarkers Market Size & Share Analysis - Growth Trends & Forecasts (2024 - 2029)